BRPI0920082A2 - forma de dosagem oral de acetaminofeno/tramadol com liberação estendida. - Google Patents

forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.

Info

Publication number
BRPI0920082A2
BRPI0920082A2 BRPI0920082A BRPI0920082A BRPI0920082A2 BR PI0920082 A2 BRPI0920082 A2 BR PI0920082A2 BR PI0920082 A BRPI0920082 A BR PI0920082A BR PI0920082 A BRPI0920082 A BR PI0920082A BR PI0920082 A2 BRPI0920082 A2 BR PI0920082A2
Authority
BR
Brazil
Prior art keywords
tramadol
dosage form
oral dosage
extended release
release acetaminophen
Prior art date
Application number
BRPI0920082A
Other languages
English (en)
Inventor
Ho Lee Domg
Hyun Kim Jae
Dong Liang-Chang
Joo Hwang Sung
Choi Tae-Hong
Wei-Guo-Dai
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41514164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920082(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0920082A2 publication Critical patent/BRPI0920082A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0920082A 2008-10-27 2009-10-23 forma de dosagem oral de acetaminofeno/tramadol com liberação estendida. BRPI0920082A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10861808P 2008-10-27 2008-10-27
PCT/US2009/061803 WO2010062524A1 (en) 2008-10-27 2009-10-23 Extended release oral acetaminophen/tramadol dosage form

Publications (1)

Publication Number Publication Date
BRPI0920082A2 true BRPI0920082A2 (pt) 2019-09-24

Family

ID=41514164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920082A BRPI0920082A2 (pt) 2008-10-27 2009-10-23 forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.

Country Status (25)

Country Link
US (1) US20100104638A1 (pt)
EP (1) EP2362768B1 (pt)
JP (1) JP5713911B2 (pt)
KR (3) KR101631140B1 (pt)
CN (2) CN102264355A (pt)
AU (1) AU2009320181B2 (pt)
BR (1) BRPI0920082A2 (pt)
CA (1) CA2741751C (pt)
CL (1) CL2011000935A1 (pt)
CO (1) CO6331423A2 (pt)
CR (1) CR20110287A (pt)
EA (1) EA023149B1 (pt)
EC (1) ECSP11011009A (pt)
ES (1) ES2582779T3 (pt)
HN (1) HN2011001184A (pt)
IL (1) IL212453A (pt)
MX (1) MX339867B (pt)
MY (1) MY161550A (pt)
NI (1) NI201100079A (pt)
NZ (1) NZ592325A (pt)
PE (1) PE20110855A1 (pt)
TW (1) TWI561257B (pt)
UA (1) UA102706C2 (pt)
WO (1) WO2010062524A1 (pt)
ZA (1) ZA201103880B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
BR112012001466A2 (pt) * 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
BR112013028668A2 (pt) * 2011-05-06 2017-01-24 Glaxosmithkline Llc formulações de paracetamol de liberação sustentada
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 Grünenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
WO2013169977A2 (en) * 2012-05-10 2013-11-14 Fmc Corporation Controlled release solid dose form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015044952A2 (en) * 2013-09-30 2015-04-02 Athena Drug Delivery Solutions Pvt Ltd. Tramadol hydrochloride and paracetamol orally disintegrating composition and process for preparing the same
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA2933983A1 (en) * 2013-12-16 2015-06-25 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법
KR20240158668A (ko) * 2023-04-27 2024-11-05 대원제약주식회사 펠루비프로펜 및 트라마돌을 포함하는 진통용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206751A (ja) * 1982-05-26 1983-12-02 日石三菱株式会社 創傷被覆材
DE122004000032I2 (de) 1991-09-06 2006-02-09 Mcneilab Inc Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO2004026308A1 (en) 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
AU2003275855B2 (en) * 2002-10-25 2009-04-23 Paladin Labs (Barbados) Inc. Sustained-release tramadol formulations with 24-hour efficacy
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
BRPI0612802A2 (pt) * 2005-07-07 2010-11-30 Farnam Co Inc composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
ES2620293T3 (es) * 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
CN1785167A (zh) * 2005-10-08 2006-06-14 王鸣 一种非麻醉性镇痛剂的复方缓释制剂的制备方法
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
PA8790401A1 (es) * 2007-07-18 2009-03-31 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8
EP2219612A4 (en) * 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic

Also Published As

Publication number Publication date
UA102706C2 (ru) 2013-08-12
CO6331423A2 (es) 2011-10-20
ES2582779T3 (es) 2016-09-15
KR20110119845A (ko) 2011-11-02
CN107028908A (zh) 2017-08-11
EP2362768B1 (en) 2016-04-20
NI201100079A (es) 2011-10-21
MY161550A (en) 2017-04-28
TWI561257B (en) 2016-12-11
CR20110287A (es) 2011-11-10
JP2012506907A (ja) 2012-03-22
KR101631140B1 (ko) 2016-06-20
KR20130137720A (ko) 2013-12-17
ZA201103880B (en) 2012-10-31
NZ592325A (en) 2012-09-28
EA201170616A1 (ru) 2011-12-30
TW201028180A (en) 2010-08-01
AU2009320181B2 (en) 2015-08-27
WO2010062524A1 (en) 2010-06-03
MX339867B (es) 2016-06-14
PE20110855A1 (es) 2011-12-05
IL212453A (en) 2017-03-30
CA2741751C (en) 2017-05-09
CN102264355A (zh) 2011-11-30
US20100104638A1 (en) 2010-04-29
KR20110036858A (ko) 2011-04-11
EA023149B1 (ru) 2016-04-29
JP5713911B2 (ja) 2015-05-07
EP2362768A1 (en) 2011-09-07
MX2011004403A (es) 2011-05-25
HK1162915A1 (zh) 2012-09-07
ECSP11011009A (es) 2011-06-30
IL212453A0 (en) 2011-06-30
CL2011000935A1 (es) 2011-10-21
AU2009320181A1 (en) 2010-06-03
HN2011001184A (es) 2014-09-01
CA2741751A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
TWI561257B (en) Extended release oral acetaminophen/tramadol dosage form
CY2018030I1 (el) Φαρμακοτεχνικη μορφη 514
EP2251005A4 (en) Orally disintegrating tablets
BRPI1012004A2 (pt) "forma farmacêutica"
BRPI0920521A2 (pt) combinação farmacêutica
DK2265144T3 (da) Pensel
BRPI0819231A2 (pt) Forma de dosagem de desintegração oral
BRPI0822722A2 (pt) Implemento para cuidado oral.
EP2263545A4 (en) sonographer
BRPI0906802A2 (pt) Implemento para cuidado oral.
SMT201700095B (is) Composizioni farmaceutiche per inalazione
NO20083238L (no) Narresmokk
PL2379086T3 (pl) Preparat farmeceutyczny
DK2285413T3 (da) Farmaceutisk sammensætning
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0922806A2 (pt) formas de dosagem oral de bendamustina
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0807882A2 (pt) Forma de dosagem
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
PT2271348T (pt) Formulação de comprimido oral de composto de tetraciclina
BRPI0912171A2 (pt) composição farmacêutica
EP2283352A4 (en) Acetaminophen TEST PROCEDURE
BRPI0921301A2 (pt) composição farmacêutica
BRPI1007237A2 (pt) composição farmacêutica compreendendo aleglitazar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.